Larry Danziger, PharmD
Executive Director, Center for Advanced Design, Research, and Exploration (CADRE)
Professor, Pharmacy Practice
Professor of Pharmacy, Medicine
833 South Wood Street
RM 164, MC 886
Chicago, IL 60612
312 996 0892
danziger@uic.edu
EDUCATION
PharmD, University of Cincinnati
BS, University of Illinois (Chicago)
BA, University of Illinois (Urbana)
CURRENT RESEARCH INTERESTS
Surgical infectious disease
Unusual properties of antimicrobial agents
Pharmacological aspects of patients with infectious diseases
SELECTED PUBLICATIONS
Jain R, Schriever CA, Danziger LH, Cho SH, Rubinstein I. The IS6110 repetitive DNA element of Mycobacterium tuberculosis is not detected in exhaled breath condensate of patients with active pulmonary tuberculosis. Respiration. 2007;74(3):329-33.
Slover CM, Rodvold KA, Danziger LH. Tigecycline: a novel broad-spectrum antimicrobial. Ann Pharmacother. 2007 Jun;41(6):965-72.
Joseph JM, Jain R, Danziger LH. Micafungin: a new echinocandin antifungal. Pharmacotherapy. 2007 Jan;27(1):53-67. Review.
Itokazu GS, Schwartz DN, Garey KW, Rodvold KA, Danziger LH, Weinstein RA. Pharmacists' perceptions of the effectiveness of antimicrobial control programs. Am J Health Syst Pharm. 2006 Dec 15;63(24):2504-8.
Sprandel KA, Drusano GL, Hecht DW, Rotschafer JC, Danziger LH, Rodvold KA. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. Diagn Microbiol Infect Dis. 2006 Aug;55(4):303-9.
Johnson MD, Kleinberg M, Danziger L, Ostrosky-Zeichner L. Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions. Expert Opin Pharmacother. 2005 Dec;6(15):2617-32. Review.
Suda KJ, Garey K, Danziger LH. Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. Pharm World Sci. 2005 Apr;27(2):81-2.